Market Overview

Argus Sees Long-Term Health In Herbalife Shares

Share:
Related HLF
Bill Ackman Vs. Herbalife: The Saga Continues...
Mid-Afternoon Market Update: Infosys Shares Decline Following Disappointing Q1 Results; Herbalife Shares Spike Higher
Herbalife: Let's Not Use Labels (Seeking Alpha)

In Argus' morning summary, analyst John Staszak‏ maintained a Hold rating on Herbalife (NYSE: HLF) following the April announcement that the Department of Justice ad FBI are investigating the company.

The analyst raised estimates following first quarter results, but noted "limited near-term upside" given investigations.

Staszak wrote, “Despite HLF's recent solid results and favorable valuation metrics, we believe that the shares have limited nearterm upside due to the current investigations of the company by the FTC and the DOJ.”

Argus raised 2014 EPS estimate from $6.05 to $6.36, above the consensus estimate of $6.24. 2015 EPS estimate was also increased from $7.10 to $7.45, above the consensus of $7.20. The analyst expects revenue to increase 11 percent in 2014 to $5.3 billion, with a five-year growth rate forecast of 18 percent.

Argus reaffirmed its five-year Buy rating on the company due to Herbalife's strong balance sheet and earnings growth potential.

Shares of Herbalife closed at $64.54 on Friday. The stock is currently trading at $63.54, down 1.57 percent.

Latest Ratings for HLF

DateFirmActionFromTo
Apr 2016BarclaysTerminatesOverweightOve
Aug 2015Pivotal ResearchMaintainsBuy
May 2015Canaccord GenuityMaintainsBuy

View More Analyst Ratings for HLF
View the Latest Analyst Ratings

Posted-In: Argus John StaszakAnalyst Color News Reiteration Legal Analyst Ratings

 

Related Articles (HLF)

View Comments and Join the Discussion!